SIEMENS LTD. - 500550 - Outcome Of Board Meeting - 12Th February 2021
Outcome of Board Meeting - 12th February 202112-02-2021
SIEMENS LTD. - 500550 - Outcome Of Board Meeting - 12Th February 2021
Outcome of Board Meeting - 12th February 2021CCI approves acquisition of Varian Medical Systems by Siemens Healthineers
The Competition Commission of India (CCI) on Wednesday said it has given nod to acquisition of 100 per cent shares and sole control of Varian Medical Systems by Siemens Healthineers. As per a combination notice filed with the regulator, the transaction relates to the acquisition of 100 per cent shares of common stock and sole control of Varian by Siemens Healthineers Holding I GmbH, which is a wholly-owned subsidiary of Siemens Healthineers AG. The proposed transaction will bring together Siemens Healthineers' imaging equipment and Varian's oncology treatment solutions, allowing for a more innovative, efficient and comprehensive oncology solutions provider, the notice said. It will benefit cancer patients with improved treatments with the goal of ultimately turning cancer into a manageable disease, which is the driving rationale for the proposed transaction, it added. "Commission approves acquisition of 100% shares & sole control of Varian Medical Systems by Siemens Healthineers,"SIEMENS LTD. - 500550 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached the information regarding issue of duplicate share certificates.Siemens ties up with IISc, CMTI to set up digital transformation labs
Siemens signed two separate memorandums of understanding (MoUs) with IISc and CMTI, respectively, to establish first-of-its-kind digital transformation labs, the company said in a statement.SIEMENS LTD. - 500550 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We refer to our letter dated 5th February, 2021 informing about the Company's next Board Meeting date. In this connection and pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the newspaper advertisements, published in Business Standard (in English) and Navshakti (in Marathi) on 6th February, 2021.SIEMENS LTD. - 500550 - Board Meeting Intimation for Board Meeting Intimation
SIEMENS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that a Meeting of the Board of Directors of the Company will be held on Friday, 12th February, 2021, to consider, inter-alia, the Un-audited Financial Results for the first quarter ended 31st December, 2020.SIEMENS LTD. - 500550 - Announcement under Regulation 30 (LODR)-Change in Directorate
In continuation to our letter dated 19th November, 2019, this is to inform you that Mr. Yezdi H. Malegam (DIN: 00092017), has ceased to be an Independent Director of the Company with effect from 30th January, 2021, upon completion of his term.SIEMENS LTD. - 500550 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached the information regarding loss of share certificate(s) received from our Registrar and Share Transfer Agent, TSR Darashaw Consultants Private Limited on 25th January, 2021.SIEMENS LTD. - 500550 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Information pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015Siemens reports stronger than expected results, to review outlook
The trains-to-factory software maker said it would review its outlook for fiscal 2021 when it publishes its first-quarter earnings in full on Feb. 3.